CPT® Code 81270

The CPT® Code 81270 refers to the molecular genetic testing specifically aimed at identifying a mutation in the JAK2 (Janus kinase 2) gene, particularly the p.Val617Phe (V617F) variant. This gene plays a crucial role in producing a protein that is integral to the JAK/STAT signaling pathway, which is responsible for transmitting chemical signals from outside the cell to the nucleus, thereby influencing various cellular functions, including the regulation of blood cell production. The JAK2 gene is located on chromosome 9 and is classified as a somatic gene mutation, meaning it is an acquired mutation rather than one inherited from parents. The presence of the JAK2 mutation is notably prevalent in individuals diagnosed with polycythemia vera, a myeloproliferative disorder characterized by the excessive production of blood cells. Specifically, the V617F variant involves a substitution of the amino acid valine with phenylalanine at position 617, resulting in the continuous activation of the JAK2 protein. This persistent activation leads to the overproduction of white blood cells, red blood cells, and platelets within the bone marrow, which can cause complications such as abnormal blood clotting, a sluggish circulatory rate, and reduced oxygen delivery to vital organs. Additionally, this mutation is also associated with other conditions such as essential thrombocytopenia, which is marked by elevated platelet levels, and primary myelofibrosis, characterized by fibrotic changes in the bone marrow. Therefore, molecular genetic testing for the JAK2 mutation is indicated for individuals exhibiting symptoms related to myeloproliferative disorders (MPD), aiding in the diagnosis and management of these conditions.